Home › NDC Lookup › Ingredients › Ketoconazole › 00168-0099-15
ketoconazole 20 mg/g Cream — NDC 00168-0099-15 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

ketoconazole 20 mg/g Cream — NDC 0168-0099-15 (Billing 00168-0099-15)

by E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC · 1 TUBE in 1 CARTON / 15 g in 1 TUBE

This is a package of ketoconazole 20 mg/g Cream from E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC, marketed since Apr 2004 and currently FDA-listed; retail pharmacies pay about $0.2848 per g (NADAC).

NDC 00168-0099-15
🏷️ FDA NDC (as labeled) 0168-0099-15 billing pads the labeler segment with a zero
This package
Contains15 g in 1 tube Cost per g$0.2848 NADAC Per package$4.27 / 15 g Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.6273/unit · Part D plans $0.3356/unit — full pricing hub ↓
Product page 00168-0099-60 Also comes in: 30 g 0168-0099-30 60 g 0168-0099-60
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Past resolved recalls for this product (1)
Class II · Apr 13, 2022 · Terminated — cGMP deviations: Temperature abuse (Mckesson Medical-Surgical Inc. Corporate Office) · FDA recall D-1065-2022

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0168-0099-15
Product NDC 0168-0099
11-digit billing NDC 00168009915
NCPDP billing unit GM — per gram (weight)
RxCUI 203088
UNII R9400W927I
UPC 0301680099156
Application # ANDA076294
SPL Set ID cad7c647-34a9-4e4e-83b3-8d78e58f588f
Established class (EPC) Azole Antifungal
Mechanism of action Cytochrome P450 3A4 Inhibitors; Cytochrome P450 3A5 Inhibitors; P-Glycoprotein Inhibitors
Chemical class Azoles
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2004-04-28
Route TOPICAL
Dosage form CREAM
Substance KETOCONAZOLE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90154045003710
GPI class Ketoconazole
GCN Seq No 007334
GCN 31850
HICL code 004132
Ingredient (HICL) Ketoconazole
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 08:14.08.00
AHFS class Azole Antifungals
FDB label name KETOCONAZOLE 2% CREAM
FDB brand name Ketoconazole
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007334
  • GCN: 31850
  • GPI-14 (Medi-Span): 90154045003710
  • HICL (First Databank): 004132
  • AHFS class code: 08:14.08.00
  • RxCUI (RxNorm): 203088
Why two NDCs? The FDA registers this code as 0168-0099-15 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00168-0099-15. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Cortisol Synthesis Inhibitor class.

Pharmacologic class Cortisol Synthesis Inhibitor, Azole Antifungal
Drug family (ATC) Anticorticosteroids, Imidazole and triazole derivatives, Imidazole derivatives
How it works Cytochrome P450 2B6 Inhibitors, Cytochrome P450 3A4 Inhibitors, Cytochrome P450 17A1 Inhibitors, P-Glycoprotein Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name KETOCONAZOLE 2% CREAM Ingredient Ketoconazole
📗 Our plain-language guide HelloPharmacist
  • It depends on the form. The tablets treat serious fungal infections like blastomycosis and histoplasmosis. The creams, foam and shampoos treat skin and scalp conditions like ringwo...
  • Take them with a meal, since that helps your body absorb them best. Follow your prescriber's directions. If you take acid-reducing medicine, ask me how to time it, because it can l...
  • Nausea, stomach upset, headache and dizziness are among the more common ones. Call your doctor right away if you notice yellow skin or eyes, dark urine, unusual tiredness, fainting...
  • The tablets have caused serious liver injury, sometimes fatal, even in people with no known liver problems. That's why you'll have liver blood tests before and during treatment. Av...
📖 Read our full Ketoconazole guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.285 $4.27 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.6273 $9.41 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.3356 $5.03 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.531 $0.260
▼ Down 43% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00168-0099-15 You're viewing this 1 TUBE in 1 CARTON / 15 g in 1 TUBE $0.2848 / g $4.27 2004-04-28 — Active
00168-0099-30 0168-0099-30 1 TUBE in 1 CARTON / 30 g in 1 TUBE $0.2486 / g $7.46 2004-04-28 — Active
00168-0099-60 0168-0099-60 Main listing 1 TUBE in 1 CARTON / 60 g in 1 TUBE $0.1622 / g $9.73 2004-04-28 — Active

Per g, this pack runs about 76% above the cheapest pack (NDC 00168-0099-60, $0.1622 vs $0.2848 NADAC).

This pack accounts for about 20% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 15 g in 1 tube.
What NDC number is used to bill for this package of ketoconazole 20 mg/g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ketoconazole 20 mg/g 71085-0008-60 IPG 1 tube $0.185 AB FDA listed save 35%
Ketoconazole 20 mg/g 00093-3219-15 Teva 1 tube $0.285 AB Availability likely —
ketoconazole 20 mg/gthis 00168-0099-15 E. 1 tube $0.285 AB Availability likely —
Ketoconazole 20 mg/g 16714-0955-01 NORTHSTAR 1 tube $0.285 AB Availability likely —
Ketoconazole 20 mg/g 21922-0025-04 Encube 1 tube $0.285 AB Availability likely —
Ketoconazole 20 mg/g 51672-1298-01 Sun 1 tube $0.285 AB Availability likely —
Ketoconazole 20 mg/g 50090-5265-00 A-S 1 tube — AB FDA listed —
Ketoconazole 20 mg/g 50090-6046-00 A-S 1 tube — AB FDA listed —
Ketoconazole 20 mg/g 50090-6069-00 A-S 1 tube — AB FDA listed —
Ketoconazole 20 mg/g 51407-0279-15 Golden 1 tube — AB FDA listed —
Ketoconazole 20 mg/g 63187-0774-15 Proficient 1 tube — AB FDA listed —
Ketoconazole 20 mg/g 63629-8819-01 Bryant 1 tube — AB FDA listed —
Ketoconazole 20 mg/g 63629-8820-01 Bryant 1 tube — AB FDA listed —
Ketoconazole 20 mg/g 68071-1709-03 NuCare 30 g — AB FDA listed —
Ketoconazole 20 mg/g 68071-3512-05 NuCare 15 tubes — AB FDA listed —
Ketoconazole 20 mg/g 68788-8233-03 Preferred 1 tube — AB FDA listed —
Ketoconazole 20 mg/g 70518-4236-00 REMEDYREPACK 1 tube — AB FDA listed —
Ketoconazole Cream 20 mg/g 72189-0422-30 Direct_Rx 30 g — AB FDA listed —
Ketoconazole 20 mg/g 82804-0091-15 Proficient 1 tube — AB FDA listed —
Ketoconazole 20 mg/g 85766-0135-15 Sportpharm 1 tube — AB FDA listed —
Ketoconazole 20 mg/g 87063-0066-15 ASCLEMED 1 tube — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2004
On the market since
Apr 2004
📍
2026
Currently FDA-listed
22 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerE. Fougera & Co. a division of Fougera Pharmaceuticals, LLC
Application holderFOUGERA PHARMACEUTICALS INC
FDA applicationANDA076294 (ANDA)
Labeler code00168
First marketedApr 2004
Product typeHuman Prescription Drug
Portfolio33 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🧒 Pediatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 60 words ▾

INDICATIONS AND USAGE Ketoconazole Cream 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare) ; in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis.

⏱️ Dosage and Administration 123 words ▾

DOSAGE AND ADMINISTRATION Cutaneous candidiasis, tinea corporis, tinea cruris, tinea pedis and tinea (pityriasis) versicolor: It is recommended that Ketoconazole Cream 2% be applied once daily to cover the affected and immediate surrounding area. Clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks in order to reduce the possibility of recurrence. Patients with tinea versicolor usually require two weeks of treatment.

Patients with tinea pedis require six weeks of treatment. Seborrheic dermatitis: Ketoconazole Cream 2% should be applied to the affected area twice daily for four weeks or until clinical clearing. If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined.

⛔ Contraindications 21 words ▾

CONTRAINDICATIONS Ketoconazole Cream 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

⚠️ Warnings 64 words ▾

WARNINGS Ketoconazole Cream 2% is not for ophthalmic use. Ketoconazole Cream 2% contains sodium sulfite anhydrous, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.

Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

🤒 Adverse Reactions 74 words ▾

ADVERSE REACTIONS During clinical trials 45 (5.0%) of 905 patients treated with Ketoconazole Cream 2% and 5 (2.4%) of 208 patients treated with placebo reported side effects consisting mainly of severe irritation, pruritus and stinging. One of the patients treated with Ketoconazole Cream developed a painful allergic reaction. In worldwide postmarketing experience, rare reports of contact dermatitis have been associated with Ketoconazole Cream or one of its excipients, namely sodium sulfite or propylene glycol.

🧒 Pediatric Use 11 words ▾

Pediatric Use: Safety and effectiveness in children have not been established.

🧬 Clinical Pharmacology ~1 min read ▾

CLINICAL PHARMACOLOGY When Ketoconazole Cream 2% was applied dermally to intact or abraded skin of Beagle dogs for 28 consecutive days at a dose of 80 mg, there were no detectable plasma levels using an assay method having a lower detection limit of 2 ng/ml. After a single topical application to the chest, back and arms of normal volunteers, systemic absorption of ketoconazole was not detected at the 5 ng/ml level in blood over a 72-hour period. Two dermal irritancy studies, a human sensitization test, a phototoxicity study and a photoallergy study conducted in 38 male and 62 female volunteers showed no contact sensitization of the delayed hypersensitivity type, no irritation, no phototoxicity and no photoallergenic potential due to Ketoconazole Cream 2%.

Microbiology: Ketoconazole is a broad spectrum synthetic antifungal agent which inhibits the in vitro growth of the following common dermatophytes and yeasts by altering the permeability of the cell membrane: dermatophytes: Trichophyton rubrum, T. mentagrophytes, T. tonsurans, Microsporum canis, M. audouini, M. gypseum and Epidermophyton floccosum; yeasts: Candida albicans, Malassezia ovale (Pityrosporum ovale) and C. tropicalis; and the organism responsible for tinea versicolor, Malassezia furfur (Pityrosporum orbiculare) .

Only those organisms listed in the INDICATIONS AND USAGE Section have been proven to be clinically affected. Development of resistance to ketoconazole has not been reported. Mode of Action: In vitro studies suggest that ketoconazole impairs the synthesis of ergosterol, which is a vital component of fungal cell membranes.

It is postulated that the therapeutic effect of ketoconazole in seborrheic dermatitis is due to the reduction of M. ovale, but this has not yet been proven.

📦 How Supplied / Storage and Handling 42 words ▾

HOW SUPPLIED Ketoconazole Cream 2% is supplied as follows: 15 gram NDC 0168-0099-15 30 gram NDC 0168-0099-30 60 gram NDC 0168-0099-60 Store below 77°F (25°C). E. FOUGERA & CO. A division of Fougera PHARMACEUTICALS INC. Melville, New York 11747 I299C R11/11 #39

📋 Description 58 words ▾

DESCRIPTION Ketoconazole Cream 2%, for topical administration only, contains the broad-spectrum synthetic antifungal agent, ketoconazole 2%, formulated in an aqueous cream vehicle consisting of propylene glycol, stearyl and cetyl alcohols, sorbitan monostearate, polysorbate 60, isopropyl myristate, sodium sulfite anhydrous, polysorbate 80 and purified water. Ketoconazole is cis -1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1 H -imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine and has the following structural formula: Structural Formula

⚠️ Precautions ~1 min read ▾

PRECAUTIONS General: If a reaction suggesting sensitivity or chemical irritation should occur, use of the medication should be discontinued. Hepatitis (1:10,000 reported incidence) and, at high doses, lowered testosterone and ACTH induced corticosteroid serum levels have been seen with orally administered ketoconazole; these effects have not been seen with topical ketoconazole. Carcinogenesis, Mutagenesis, Impairment of Fertility: A long-term feeding study in Swiss Albino mice and in Wistar rats showed no evidence of oncogenic activity.

The dominant lethal mutation test in male and female mice revealed that single oral doses of ketoconazole as high as 80 mg/kg produced no mutation in any stage of germ cell development. The Ames' Salmonella microsomal activator assay was also negative. Pregnancy: Teratogenic effects: Pregnancy Category C: Ketoconazole has been shown to be teratogenic (syndactylia and oligodactylia) in the rat when given orally in the diet at 80 mg/kg/day, (10 times the maximum recommended human oral dose).

However, these effects may be related to maternal toxicity, which was seen at this and higher dose levels. There are no adequate and well-controlled studies in pregnant women. Ketoconazole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: It is not known whether Ketoconazole Cream 2% administered topically could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use: Safety and effectiveness in children have not been established.

🍼 Nursing Mothers 50 words ▾

Nursing Mothers: It is not known whether Ketoconazole Cream 2% administered topically could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 64 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility: A long-term feeding study in Swiss Albino mice and in Wistar rats showed no evidence of oncogenic activity. The dominant lethal mutation test in male and female mice revealed that single oral doses of ketoconazole as high as 80 mg/kg produced no mutation in any stage of germ cell development. The Ames' Salmonella microsomal activator assay was also negative.

📄 Package Label / Principal Display Panel 100 words ▾

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15 G CONTAINER NDC 0168-0099-15 FOUGERA ® KETOCONAZOLE CREAM 2% For dermatologic use only. Rx only Contains ketoconazole 20 mg/g, propylene glycol, stearyl and cetyl alcohols, sorbitan monostearate, polysorbate 60, isopropyl myristate, sodium sulfite anhydrous, polysorbate 80 and purified water. NET WT 15 grams tube15gram

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15 G CARTON NDC 0168-0099-15 Rx only FOUGERA ® KETOCONAZOLE CREAM 2% For dermatologic use only. Warning: Not for ophthalmic use. Keep out of reach of children. NET WT 15 grams PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 15 G CARTON

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
59K
Units reimbursed last 4 qtrs
1.2M
Gross reimbursed last 4 qtrs
$763.2K
Avg / prescription
$12.95
Avg / unit
$0.6273
Latest quarter Q1 2026
13.2KRx
Medicaid pays / g
$0.6273
gross reimbursed
vs
NADAC / g
$0.2848
acquisition cost
=
Spread
+$0.3425
+120% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
38% FFS 62% MCO
Fee-for-service · 22,278 Rx Managed care · 36,676 Rx
State Medicaid map
Alaska: no data reported AK Maine: 8,565 units · 614 per 100k residents ME Washington: 12,420 units · 159 per 100k residents WA Idaho: 3,135 units · 160 per 100k residents ID Montana: 1,290 units · 114 per 100k residents MT North Dakota: no data reported ND Minnesota: 11,035 units · 192 per 100k residents MN Wisconsin: 8,460 units · 143 per 100k residents WI Michigan: 32,535 units · 324 per 100k residents MI New York: 302,065 units · 1,543 per 100k residents NY Vermont: 3,600 units · 556 per 100k residents VT New Hampshire: 3,330 units · 238 per 100k residents NH Oregon: 2,100 units · 49.6 per 100k residents OR Nevada: 2,580 units · 80.8 per 100k residents NV Wyoming: no data reported WY South Dakota: 1,576 units · 171 per 100k residents SD Iowa: 18,240 units · 569 per 100k residents IA Illinois: 26,235 units · 209 per 100k residents IL Indiana: 24,857 units · 362 per 100k residents IN Ohio: 51,255 units · 435 per 100k residents OH Pennsylvania: 64,660 units · 499 per 100k residents PA New Jersey: 258,725 units · 2,785 per 100k residents NJ Massachusetts: 11,237 units · 161 per 100k residents MA California: 75,695 units · 194 per 100k residents CA Utah: 2,445 units · 71.6 per 100k residents UT Colorado: 5,595 units · 95.2 per 100k residents CO Nebraska: 2,670 units · 135 per 100k residents NE Missouri: 7,440 units · 120 per 100k residents MO Kentucky: 10,761 units · 238 per 100k residents KY West Virginia: 6,540 units · 369 per 100k residents WV Virginia: 19,485 units · 224 per 100k residents VA Maryland: 47,400 units · 767 per 100k residents MD Connecticut: 18,765 units · 519 per 100k residents CT Rhode Island: 2,685 units · 245 per 100k residents RI Arizona: 6,720 units · 90.4 per 100k residents AZ New Mexico: 2,491 units · 118 per 100k residents NM Kansas: 1,860 units · 63.3 per 100k residents KS Arkansas: no data reported AR Tennessee: 8,175 units · 115 per 100k residents TN North Carolina: 24,840 units · 229 per 100k residents NC South Carolina: 6,045 units · 113 per 100k residents SC Delaware: 2,025 units · 196 per 100k residents DE Oklahoma: 5,250 units · 130 per 100k residents OK Louisiana: 10,575 units · 231 per 100k residents LA Mississippi: 1,530 units · 52.0 per 100k residents MS Alabama: 5,715 units · 112 per 100k residents AL Georgia: 36,825 units · 334 per 100k residents GA D.C.: 9,970 units · 1,468 per 100k residents DC Hawaii: 2,430 units · 169 per 100k residents HI Texas: 12,045 units · 39.5 per 100k residents TX Florida: 32,817 units · 145 per 100k residents FL
Units reimbursed · per 100k residents
39.52,785
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Jersey 2,785 /100k
2 New York 1,543 /100k
3 D.C. 1,468 /100k
4 Maryland 767 /100k
5 Maine 614 /100k
6 Iowa 569 /100k
7 Vermont 556 /100k
8 Connecticut 519 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube00168-0099-60 146,837 Rx · $3,084,375
1 tube00168-0099-30 86,389 Rx · $1,485,184
1 tube this page00168-0099-15 58,954 Rx · $763,178
Drug total (last 4 qtrs): 292,180 Rx · 13,370,400 units · $5,332,738 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Ketoconazole — the program that covers self-administered drugs. 13 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Ketoconazole. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$20.47M
Claims incl. refills
1.2M
Beneficiaries
831.7K
Spend / beneficiary
$24.61
Spend / claim
$17.69
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 00168-0080-16 · E. 00168-0126-91 · Fougera →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.